FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC
AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.
Related Articles
Finding the ‘Right Fit’ for ER+ Breast Cancer After Aromatase Inhibitor AEs
A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast cancer.
TAB-Follicular Lymphoma
Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.
Cilta-Cel Shows ‘Promising Efficacy, Safety’ in Newly Diagnosed MM | Blood Cancers Today
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM who have had suboptimal response to frontline…
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma
Jeffrey Graham University of Manitoba Ardalan E. Ahmad University of Manitoba Naveen S. Basappa University of Alberta Jean-Christophe Bernhard CHU de Bordeaux, France Bimal Bhindi…
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis
A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.
A mom’s journey is a sign of hope for starting a family after cancer treatment
Little Penelope Lo Destro’s parents were about to start their family when there was a terrible diagnosis.
Erba Explores myeloMATCH Substudies Targeting Genetic Diversity in AML, MDS
Harry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.
Palliative Approach to Care an Untapped Benefit for Patients With Multiple Myeloma – Oncology Nurse Advisor
Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.
Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma
Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.